A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab.

MLA

Ghazawi, Feras M., et al. “A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab.” Frontiers in Medicine, vol. 8, Aug. 2021, p. 702776. EBSCOhost, https://doi.org/10.3389/fmed.2021.702776.

APA

Ghazawi, F. M., Mahmood, F., Kircik, L., Poulin, Y., Bourcier, M., Vender, R., Wiseman, M. C., Lynde, C., & Litvinov, I. V. (2021). A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab. Frontiers in Medicine, 8, 702776. https://doi.org/10.3389/fmed.2021.702776

Chicago

Ghazawi, Feras M, Farhan Mahmood, Leon Kircik, Yves Poulin, Marc Bourcier, Ronald Vender, Marni C Wiseman, Charles Lynde, and Ivan V Litvinov. 2021. “A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab.” Frontiers in Medicine 8 (August): 702776. doi:10.3389/fmed.2021.702776.